EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study

Hiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, Aya Suzuki, Akihiko Miyanaga, Masahiro Seike, Koichi Azuma, Hajime Asahina, Akira Kisohara, Yosuke Kawashima, Hisashi Tanaka, Ryota Kanemaru und 10 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115693 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Hiromi Nagashima und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University, Shiwa-gun, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Afatinib, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAfatinibLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMutationHumansPemetrexedFemaleMaleCarboplatinMiddle AgedAgedAcrylamidesErbB ReceptorsAniline CompoundsAdultDrug Resistance, NeoplasmAged, 80 and overProgression-Free SurvivalIndolesPyrimidines

Stichwörter der Autor:innen

AfatinibCombination chemotherapyOsimertinib resistance

Substanzen

PemetrexedAfatinibCarboplatinosimertinibAcrylamidesErbB ReceptorsAniline CompoundsEGFR protein, humanIndolesPyrimidines

Autor:innen und Institutionen

  • Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University, Shiwa-gun, Japan.
  • Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
  • Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Department of Respiratory Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Respiratory Medicine, Kasukabe Medical Center, Kasukabe, Japan.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Nagashima, H., Fukuhara, T., Utsumi, Y., Suzuki, A., Miyanaga, A., Seike, M., Azuma, K., Asahina, H., Kisohara, A., Kawashima, Y., Tanaka, H., Kanemaru, R., Miyauchi, E., Furuya, N., Sato, H., Nakashima, K., Watanabe, S., Sakai, K., Nishio, K., …, & Maemondo, M. (2025). A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115693

Vancouver

Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, Miyanaga A, Seike M, et al. A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115693

BibTeX
@article{Nagashima2025,
  author = {Nagashima, Hiromi and Fukuhara, Tatsuro and Utsumi, Yu and Suzuki, Aya and Miyanaga, Akihiko and Seike, Masahiro and Azuma, Koichi and Asahina, Hajime and Kisohara, Akira and Kawashima, Yosuke and Tanaka, Hisashi and Kanemaru, Ryota and Miyauchi, Eisaku and Furuya, Naoki and Sato, Haruna and Nakashima, Kazuhisa and Watanabe, Satoshi and Sakai, Kazuko and Nishio, Kazuto and Takahashi, Fumiaki and Kobayashi, Kunihiko and Maemondo, Makoto},
  title = {A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115693}
}
Kostenlos starten →